WILMINGTON, Delaware, Aug. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TAGRISSO(R) (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

First global Phase III trial to show significant progression-free and overall survival benefits in this setting